Revance Therapeutics (RVNC) Tops Q3 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.60), $0.09 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $75 thousand, versus $158 thousand reported last year.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
• Hyundai Partners with Atlanta Braves Through 2029 Season